PR Newswire: news distribution, targeting and monitoring
2014

Veloxis Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

Share with Twitter Share with LinkedIn

HORSHOLM, Denmark, Aug. 4, 2011 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma, today announced that William J. Polvino, M.D., president and chief executive officer, will present at the Canaccord Genuity Annual Growth Conference at 4 p.m. EDT on Tuesday, August 9, at the InterContinental Hotel in Boston. Dr. Polvino will provide an overview of the company and its lead Phase 3 candidate, LCP-Tacro™, to prevent organ transplant rejection.  He will also discuss recently-announced top-line results of the first Phase 3 trial in stable kidney transplant patients.

About Veloxis Pharmaceuticals A/S

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
(732) 321-3208
jdw@veloxis.com

SOURCE Veloxis Pharmaceuticals A/S



RELATED LINKS
http://www.veloxis.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release